Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 26Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Lung Neoplasms 6Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasms 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Neurofibrosarcoma 2Neoplasm Metastasis 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Cholangiocarcinoma 2

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Radiation Dose Hypofractionation × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡